In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Abbott acquires Action Pharma's Phase II renal compound AP214

Executive Summary

Private Danish biotech Action Pharma AS has sold Abbott Laboratories Inc. its Phase IIb hormone analogue AP214 for preventing at-risk patients from acute kidney injury (AKI) associated with major cardiac surgery.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register